GAINESVILLE, FL; April 26, 2017- Upon graduating from the University of Florida’s Innovation Hub, local biotechnology company, Captozyme Inc., recently acquired a newly constructed facility to house their new headquarters at 1622 NW 55th Place. The company plans to consolidate all operations there during the coming months, and is proud to be part of the developing biotechnology scene of Gainesville.
Captozyme was recently honored in being one of the 20 companies chosen to present at the Florida Venture Forum out of more than 100 applicants. The Florida Venture Forum's mission is to connect emerging Florida-based companies with resources and capital nationwide.
“The Conference is always a must-attend event for anyone involved in the venture capital and private equity industry in Florida,” added Casey Swercheck, Chairman of the 2017 Florida Venture Capital Conference and Vice President of Capitala Group.
This year the conference was held in Orlando, Florida on February 2-3.
Captozyme will be attending the 13th Annual BioFlorida Celebration of Biotechnology at Progress Corporate Park in Alachua, FL.
Join us and many other exhibitors to network and learn about what's new within the biotech community!
Event Time: 9:30am-1:00pm - May 12th, 2016
When most people hear of someone with a kidney stone, they often assume that every kidney stone is the same. While easy to assume, this is simply not true, and there are important distinctions to be made for different kinds of kidney stones. Each stone is formed from different kinds of materials, and therefore can be prevented with different diets or interventions. For example, with calcium oxalate stones, one might want to reduce oxalate in the diet. However, if the stone does not include oxalate, then this advice and change in diet would be unnecessary. In order to uncover what type of stone someone has, the type of stone can be determined by a doctor after it has been passed, or by identifying the chemicals in one’s blood or urine.
There are five more common kidney stones, starting with the most common; calcium oxalate.
Calcium oxalate stones are comprised of calcium oxalate, and there are two different forms of this type. Calcium oxalate monohydrate, and calcium oxalate dihydrate. Calcium oxalate monohydrate stones are harder and more resistant to fragmentation, and appear more often with higher levels of oxalate.
Calcium phosphate stones are the second most common stones, and is the bonding of calcium to phosphate instead of oxalate. There are also two different kinds of these stones, and they can form into either brushite or hydroxyapatite. Brushite is extra hard and resistant to shock treatments, while hydroxyapatite can actually plug the kidney tubules and injure kidney cells.
Uric acid kidney stones are about as common as calcium phosphate stones, but are different. Uric acid is a breakdown product of DNA and RNA, and forms when the urine is too acidic. The stones are red or orange, and can form rapidly. Uric acid does not have to bond with any other chemicals like calcium phosphate or oxalate, and therefore can form in seconds, but can also be passed quickly unless the stones are retained in the kidney. If so, they can grow to become quite large. However, since they are dependent on the acidity of the urine, they can be treated with alkali supplement. Occasionally though, uric acid stones might mix with calcium oxalate stones, which can be much more difficult to break up.
The second to last of the more common stones are struvite stones. These kidney stones are a combination of magnesium, ammonium, and phosphate, and cannot be made by the kidneys themselves. They are only able to exist because of the workings of bacteria. The soil bacteria from outside can find its way into our systems, bringing with it the ability to convert urea to ammonia, which then crystallizes with magnesium and phosphate, which are always found in urine. The stones can become large, and the bacteria can injure the kidneys, or enter the bloodstream and cause sepsis.
The last of these kidney stones are cystine stones, which are only formed in those with cystinuria; an inherited kidney disease. These stones come from cysteine, and grow to be extremely large, grow quickly, and can cause damage to the kidneys cells if not treated.
While these five are the main stones found in humans, there are a few kidney stones that are much more rare, and often are forms of mixed stones. As seen in the varying types of stones, there is much more to the condition than the broad terminology of a simple kidney stone.
1. Coe, F. Type of Kidney Stones – A Primer. Retrieved from URL: http://kidneystones.uchicago.edu/types-of-stones/
2. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). (2013 November). Diet for Kidney Stone Prevention. Retrieved from URL: http://www.niddk.nih.gov/health-information/health-topics/urologic-disease/diet-for-kidney-stone-prevention/Pages/facts.aspx
The NIH Commercialization Accelerator Program (CAP) is designed to help some of the agency’s most promising small life science and healthcare Phase II grantees develop their commercial businesses and transition their SBIR/STTR-funded technologies into the marketplace. Applicants are selected via a competitive process for a limited number of slots in the program.
See more information here: https://sbir.nih.gov/cap
This magazine is full of area economic development, business climate and quality of life information. You can read it online here:
Thursday, May 7th 2015
Interested in hearing about our ongoing and upcoming projects?
Join us along with many other vendors in attending the 12th annual BioFlorida Celebration of Biotechnology at Progress Corporate Park in Alachua, FL.
Location: RTI Surgical, Alachua, FL
Event Time: 9:30am-1:00pm
Captozyme will be attending the Natural Products Expo West in Anaheim, California to explore and connect with thousands of vendors within the natural, organic and healthy lifestyle industry.
Partner Visit, Wuhan, China
Captozyme's management team will visit Wuhan “Optics Valley” to further explore business relationships. “Optics Valley” or Donghu New Technology Development Zone is one of the Technology Development Zones in China, located in the east of Wuchang District in Wuhan. In 2011 it was designated as a New Technology Development Zone for Optical Technology, and since then been self-labeled as the “Optics Valley” of China.
Edwards Wildman LLP has approved Captozyme LLC into the Firm's Helping Innovators Thrive (HIT) program. The Firm only admits early stage companies that propose innovative technologies or business concepts into its HIT program. The acceptance into the HIT program will provide Captozyme with non-standard billing arrangements tailored to its needs.
Captozyme is pleased to announce the promotion of Ms. Helena Cowley, MS to Chief Operating Officer. Ms. Cowley has been an integral part of the founding team since the inception and has been managing operations since 2013.
In September of 2014, Captozyme LLC was the recipient of a Phase II Small Business Innovation Research Grant in the amount of $1.008 million from the NIDDK/NIH for the proposed work on reduction of dietary oxalate by means of a proprietary enzyme technology.